NO20072214L - 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1 - Google Patents

6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1

Info

Publication number: NO20072214L
Authority: NO; Norway
Prior art keywords: protein kinase; pyridinyl; inhibitors; tau protein; pyrimidone derivatives
Prior art date: 2004-09-29

Application number

NO20072214A

Other languages

English (en)

Norwegian (no)

Inventor

Fumiaki Uehara

Shinsuke Hiki

Kenji Fukunaga

Toshiyuki Kohara

Kazutoshi Watanabe

Satoshi Yokoshima

Original Assignee

Mitsubishi Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2007-04-27

Publication date

2007-06-12

2007-04-27 Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp

2007-06-12 Publication of NO20072214L publication Critical patent/NO20072214L/no

Links

RLWZHQRRTCKCEF-UHFFFAOYSA-N 6-pyridin-2-yl-1h-pyrimidin-4-one Chemical class N1=CNC(=O)C=C1C1=CC=CC=N1 RLWZHQRRTCKCEF-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
102000013498 tau Proteins Human genes 0.000 title 1
108010026424 tau Proteins Proteins 0.000 title 1
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20072214A 2004-09-29 2007-04-27 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1 NO20072214L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004313115		2004-09-29
PCT/JP2005/018497 WO2006036015A2 (en)	2004-09-29	2005-09-29	6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (1)

Publication Number	Publication Date
NO20072214L true NO20072214L (no)	2007-06-12

Family

ID=35848411

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072214A NO20072214L (no)	2004-09-29	2007-04-27	6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1

Country Status (25)

Country	Link
US (1)	US8129377B2 (de)
EP (3)	EP2266969A3 (de)
JP (1)	JP5186213B2 (de)
KR (1)	KR20070057931A (de)
CN (1)	CN101048397A (de)
AR (1)	AR051823A1 (de)
AT (1)	ATE499356T1 (de)
AU (1)	AU2005288045B2 (de)
BR (1)	BRPI0515851A (de)
CA (1)	CA2581179A1 (de)
CY (1)	CY1112326T1 (de)
DE (1)	DE602005026546D1 (de)
DK (1)	DK1805164T3 (de)
EA (1)	EA013004B1 (de)
ES (1)	ES2359071T3 (de)
IL (1)	IL182223A0 (de)
MX (1)	MX2007003722A (de)
NO (1)	NO20072214L (de)
NZ (1)	NZ554722A (de)
PL (1)	PL1805164T3 (de)
PT (1)	PT1805164E (de)
SI (1)	SI1805164T1 (de)
TW (1)	TWI354669B (de)
WO (1)	WO2006036015A2 (de)
ZA (1)	ZA200703383B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR050865A1 (es) *	2004-09-09	2006-11-29	Sanofi Aventis	Derivados de 2- morfolino-4-pirimidona
GB0510142D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds A1
GB0510141D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en)	2006-03-15	2008-03-16	Mitsubishi Pharma Corp	2-(cyclic amino)-pyrimidone derivatives
CN101528729A (zh) *	2006-08-23	2009-09-09	辉瑞产品公司	作为gsk-3抑制剂的嘧啶酮化合物
WO2008026046A1 (en) *	2006-08-30	2008-03-06	Pfizer Products Inc.	Morpholine d3 dopamine antagonists
AR064660A1 (es) *	2006-12-26	2009-04-15	Mitsubishi Tanabe Pharma Corp	Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
DK2195293T3 (da)	2007-08-22	2014-02-03	Astrazeneca Ab	Cyclopropylamidderivater
TW200927134A (en)	2007-09-14	2009-07-01	Mitsubishi Tanabe Pharma Corp	6-pyrimidinyl-pyrimid-2-one derivative
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
WO2011019090A1 (en) *	2009-08-13	2011-02-17	Mitsubishi Tanabe Pharma Corporation	Pyrimidone derivatives used as tau protein kinase 1 inhibitors
JPWO2011062194A1 (ja)	2009-11-18	2013-04-04	武田薬品工業株式会社	アミノピリジン誘導体
US9452980B2 (en) *	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
BR112012020629A2 (pt)	2010-02-18	2018-06-19	Astrazeneca Ab	forma cristalina, e, método para a terapia de um distúrbio
EP2568812B1 (de) *	2010-05-11	2016-10-26	Merck Sharp & Dohme Corp.	Neuartige prolylcarboxypeptidase-hemmer
EP2928473B1 (de)	2012-12-07	2017-06-28	Merck Sharp & Dohme Corp.	Regioselektive n-2-arylierung von indazolen
MA48475A (fr)	2017-04-24	2020-03-04	Tesaro Inc	Procédés de fabrication de niraparib
CN117143079A (zh) *	2018-11-06	2023-12-01	上海奕拓医药科技有限责任公司	一种螺芳环化合物及其应用
CN111704611B (zh) *	2019-07-25	2022-01-14	上海凌达生物医药有限公司	一类芳基螺环类shp2抑制剂化合物、制备方法和用途
MX2023003841A (es) *	2020-10-06	2023-06-23	De Shaw Res Llc	Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR023052A1 (es) *	1998-09-25	2002-09-04	Mitsuharu Yoshimura Milton	Derivados de pirimidona
EP1136483A1 (de)	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-[Piperazinyl]pyrimidonderivate
EP1136482A1 (de)	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
IL160701A0 (en)	2001-09-21	2004-08-31	Mitsubishi Pharma Corp	3-substituted-4-pyrimidone derivatives
IL160700A0 (en) *	2001-09-21	2004-08-31	Mitsubishi Pharma Corp	3-substituted-4-pyrimidone derivatives
EP1454908B1 (de) *	2003-03-07	2008-02-27	Sanofi-Aventis	Substituierte Pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinonderivate
TWI357408B (en)	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives

2005
- 2005-09-29 CN CNA2005800330250A patent/CN101048397A/zh active Pending
- 2005-09-29 AR ARP050104099A patent/AR051823A1/es not_active Application Discontinuation
- 2005-09-29 CA CA002581179A patent/CA2581179A1/en not_active Abandoned
- 2005-09-29 PL PL05790292T patent/PL1805164T3/pl unknown
- 2005-09-29 BR BRPI0515851-6A patent/BRPI0515851A/pt not_active IP Right Cessation
- 2005-09-29 ZA ZA200703383A patent/ZA200703383B/xx unknown
- 2005-09-29 EP EP10010450A patent/EP2266969A3/de not_active Withdrawn
- 2005-09-29 AT AT05790292T patent/ATE499356T1/de active
- 2005-09-29 KR KR1020077008236A patent/KR20070057931A/ko not_active Ceased
- 2005-09-29 WO PCT/JP2005/018497 patent/WO2006036015A2/en not_active Ceased
- 2005-09-29 JP JP2007533116A patent/JP5186213B2/ja not_active Expired - Fee Related
- 2005-09-29 DK DK05790292.6T patent/DK1805164T3/da active
- 2005-09-29 MX MX2007003722A patent/MX2007003722A/es active IP Right Grant
- 2005-09-29 US US11/576,062 patent/US8129377B2/en not_active Expired - Fee Related
- 2005-09-29 EP EP10010448A patent/EP2261224A3/de not_active Withdrawn
- 2005-09-29 ES ES05790292T patent/ES2359071T3/es not_active Expired - Lifetime
- 2005-09-29 AU AU2005288045A patent/AU2005288045B2/en not_active Ceased
- 2005-09-29 SI SI200531256T patent/SI1805164T1/sl unknown
- 2005-09-29 TW TW094134059A patent/TWI354669B/zh not_active IP Right Cessation
- 2005-09-29 NZ NZ554722A patent/NZ554722A/en not_active IP Right Cessation
- 2005-09-29 EP EP05790292A patent/EP1805164B9/de not_active Expired - Lifetime
- 2005-09-29 PT PT05790292T patent/PT1805164E/pt unknown
- 2005-09-29 DE DE602005026546T patent/DE602005026546D1/de not_active Expired - Lifetime
- 2005-09-29 EA EA200700756A patent/EA013004B1/ru not_active IP Right Cessation
2007
- 2007-03-27 IL IL182223A patent/IL182223A0/en unknown
- 2007-04-27 NO NO20072214A patent/NO20072214L/no not_active Application Discontinuation
2011
- 2011-05-04 CY CY20111100427T patent/CY1112326T1/el unknown

Also Published As

Publication number	Publication date
CA2581179A1 (en)	2006-04-06
WO2006036015A2 (en)	2006-04-06
MX2007003722A (es)	2007-05-23
ZA200703383B (en)	2009-05-27
PL1805164T3 (pl)	2011-07-29
EP1805164A2 (de)	2007-07-11
BRPI0515851A (pt)	2008-08-12
EP2261224A2 (de)	2010-12-15
WO2006036015A3 (en)	2006-06-01
EA200700756A1 (ru)	2007-10-26
DK1805164T3 (da)	2011-05-16
EP2266969A2 (de)	2010-12-29
AU2005288045A2 (en)	2008-05-29
JP2008514587A (ja)	2008-05-08
EP2266969A3 (de)	2011-02-16
AU2005288045A1 (en)	2006-04-06
NZ554722A (en)	2010-07-30
US8129377B2 (en)	2012-03-06
TW200626573A (en)	2006-08-01
EP1805164B1 (de)	2011-02-23
CN101048397A (zh)	2007-10-03
ES2359071T3 (es)	2011-05-18
PT1805164E (pt)	2011-04-11
EP1805164B9 (de)	2011-09-07
TWI354669B (en)	2011-12-21
IL182223A0 (en)	2007-09-20
EA013004B1 (ru)	2010-02-26
EP2261224A3 (de)	2011-02-16
KR20070057931A (ko)	2007-06-07
AR051823A1 (es)	2007-02-14
JP5186213B2 (ja)	2013-04-17
CY1112326T1 (el)	2015-12-09
DE602005026546D1 (de)	2011-04-07
AU2005288045B2 (en)	2011-08-18
US20090239864A1 (en)	2009-09-24
SI1805164T1 (sl)	2011-05-31
ATE499356T1 (de)	2011-03-15

Legal Events

Date	Code	Title	Description
2013-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072214L (no)	2007-06-12	6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1
NO20071787L (no)	2007-05-09	2-morfolin-4-pyrimidonforbindelse
NO20084302L (no)	2008-12-03	2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20073926L (no)	2007-10-01	Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20070907L (no)	2007-04-16	Pyrrolo-pyridin kinase modulatorer
NO20090202L (no)	2009-03-23	Prolylhydroksylaseinhibitorer
NO20064726L (no)	2006-12-22	Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20054952L (no)	2005-10-25	2,3,6-trisubstituerte 4-pyrimidonderivater
NO20092759L (no)	2009-08-25	2-substituerte-6-heterosykliske pyrimidonderivater som tauproteinkinase-1-inhibitorer
NO20082496L (no)	2008-07-24	Pyrazinderivater
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
NO20073859L (no)	2007-10-03	Pyrrolopyrazoler, potente kinaseinhibitorer
NO20062370L (no)	2006-07-18	Amidderivater
NO20070258L (no)	2007-01-15	Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20073170L (no)	2007-06-22	Kaspaseinhibitorer og anvendelse derav
NO20062726L (no)	2006-06-12	Nye pyridazin-3(2H)-on derivater
NO20063449L (no)	2006-07-27	Substituerte heterocykler og deres anvendelse
NO20073791L (no)	2007-08-30	Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
ATE493418T1 (de)	2011-01-15	Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
NO20071314L (no)	2007-05-10	Peptidiske vasopressinreseptoragonister
NO20054331L (no)	2005-12-21	Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EA201070366A1 (ru)	2010-08-30	3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
EA201070367A1 (ru)	2010-08-30	Производное 6-пиримидинилпиримид-4-она
NO20064344L (no)	2006-10-19	Caspaseinhibitorer og anvendelser derav